Source: Tierrablanca-Sánchez, L., et al. Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method. J. Vis. Exp. (2017)
This video demonstrates a technique for assessing the efficacy of antibodies against tumor necrosis factor-alpha (TNFα), an inflammatory cytokine, through an in vitro bioanalytical approach. TNFα, when introduced to stressed cells, triggers apoptosis. However, binding to the antibodies confines TNFα, averting apoptosis. The degree of apoptosis is quantified using a bioluminescence assay.
1. Preparation of the Media and Solutions
2. Cell Culturing and Counting
3. Antibody Preparation and Dilutions
4. Neutralization Assay with WEHI 164 Cells
5. Analysis of Results
Table 1: Microplate sample arrays. A complete neutralization assay must be run in three microplates within coordinates B2 to G11. Random dispensing of reference, analytical, and control samples allows researchers to verify any bias in the assay.
Plate 1 | Plate 2 | Plate 3 | |||
Wells | Sample | Wells | Sample | Wells | Sample |
B2:B11 | Reference Substance | B2:B11 | Control Sample | B2:B11 | Analytical Sample |
C2:C11 | C2:C11 | C2:C11 | |||
D2:D11 | Analytical Sample | D2:D11 | Reference Substance | D2:D11 | Control Sample |
E2:E11 | E2:E11 | E2:E11 | |||
F2:F11 | Control Sample | F2:F11 | Analytical Sample | F2:F11 | Reference Substance |
G2:G11 | G2:G11 | G2:G11 |
Table 2: Anti-TNFα mAb dilutions. Serial dilutions of anti-TNFα mAbs are demonstrated in this table. Final concentrations described in this table are not the concentrations in the assay, where anti-TNFα mAbs were diluted by a factor of 3 (mAb dilution + culture medium + cells suspension). Lines in bold represent dilutions coming from lines 3, 5, 7, 9, and 10; non-bolded lines represent dilution from lines 3, 4, and 6. These serial dilutions are done just before performing the neutralization assay. Care must be taken to mix by pipetting up and down three times before dispensing the dilutions.
Plate Column | Volume of Assay culture medium (μL) | Volume of Reference Substance, Analytical Sample, or Control Sample (uL) | Concentration in the Assay Plate (ng/mL) |
2 | 0 | 230 | 2000 |
3 | 150 | 150 from line 2 | 1000 |
4 | 75 | 75 from line 3 | 500 |
5 | 100 | 50 from line 3 | 333 |
6 | 75 | 75 from line 4 | 250 |
7 | 75 | 75 from line 5 | 166 |
8 | 75 | 75 from line 6 | 125 |
9 | 75 | 75 from line 7 | 83 |
10 | 75 | 75 from line 9 | 41 |
11 | 150 | 75 from line 10 | 13 |
Figure 1: Disposition of samples in the assay plates. B1 to G11 are well coordinates in the microplates and describe the positions where the sample dilutions are placed. Missing coordinates are wells filled with controls and assay culture medium (A1-A12 and H1-H12). This random distribution of samples (forward and reverse dilutions in the microplates) helps to eliminate bias in the results due to the evaporation of the medium or other variables. It is best that each microplate is done by one analyst at a time. R: Reference, S: sample, CS: control sample, Dil: dilution.
Figure 2: Dose-response curve. Anti-TNFα mAb concentration versus luminescence (cell viability) is depicted. A fourth parameter equation describing the anti-TNFα protection of mAbs was used as a model. EC50 is the concentration of mAb that can neutralize the amount of TNFα that causes 50% cell death in each assay, exemplified in the graph as the change in slope. Bars describe the standard deviation of luminescence for each mAb concentration. x represents anti-TNFα Ab concentration and is depicted as a logarithmic function in ng/mL, while y represents the luminescence response in arbitrary luminescence units
Figure 3: Mathematical equation used for calculating the EC50s and their values. EC50 values, or C parameters, have their uncertainty depicted as standard error. A comparison of EC50s between the sample and reference results of relative potency is also depicted. The confidence interval is calculated with an α = 0.05.
The authors have nothing to disclose.
WEHI 164 | ATCC | CRL-1751 | Fibrosarcoma cells from Mus musculus |
RPMI-1640 Medium | ATCC | 30-2001 | Store medium at 2 °C to 8 °C |
RPMI 1640 Medium, no phenol red | GIBCO | 11835-030 | Store medium at 2 °C to 8 °C |
Trypsin-EDTA(0.25%),phenol red | GIBCO | 25200-056 | Store medium at -10 °C to -20 °C |
DPBS, no calcium, no magnesium | GIBCO | 14190-136 | Store medium at 2 °C to 8 °C |
Recombinant Human TNF-alpha Protein | R&D Systems | 210-TA-020 | Store at -20 °C to -70 °C |
Fetal Bovine Serum (U.S), Super Low IgG | HyClone | SH3089803 | Store at -10 °C to -20 °C |
Fetal Bovine Serum (U.S.), Characterized | HyClone | SH3007103 | Store at -10 °C to -20 °C |
Caspase-Glo 3/7 Assay kit | Promega | G8093 | Store the Caspase-Glo. 3/7 Substrate and Caspase-Glo. 3/7 Buffer at –20 ºC protected fromLight |
EDTA, Disodium Salt, Dihydrate, Crystal, A.C.S. Reagent | J.T.Baker | 8993-01 | — |
Sample mAb Adalimumab | Probiomed | NA | Final concentrations in the microplate are: 0.666, 0.333, 0.167, 0.111, 0.083, 0.056, 0.042, 0.028, 0.014 and 0.004 μg/mL |
Reference and Control mAb Adalimumab | Abbvie | NA | Final concentrations in the microplate are: 0.666, 0.333, 0.167, 0.111, 0.083, 0.056, 0.042, 0.028, 0.014 and 0.004 μg/mL |
Microplate Reader | Molecular Devices | 89429-536 | SpectraMax M3 Multi-Mode |
Microplate reader Software | Molecular Devices | — | SoftMax Pro 6.3 GxP |
Incubator | Revco | 30482 | Revco RNW3000TABB Forced-Air CO2 |
Laminar Flow Hood | The Baker Company | 200256 | Baker SG603A-HE | High Efficiency, Class II Type A2 |